Venous Thromboembolism Prevention in Outpatients With Glioma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.
• Age 18 and old
• Karnofsky performance status (KPS) 60-100
• Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
• Ability to provide informed consent.
• Planning for treatment with radiation and chemotherapy.
Locations
United States
Vermont
University of Vermont Medical Center
RECRUITING
Burlington
Contact Information
Primary
Alissa A Thomas, MD
alissa.thomas@med.uvm.edu
802-847-8400
Backup
Donna Silver
irb@uvm.edu
802-656-5040
Time Frame
Start Date: 2023-01-16
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 40
Treatments
Experimental: Single arm study
Related Therapeutic Areas
Sponsors
Collaborators: MaineHealth, Dartmouth-Hitchcock Medical Center
Leads: University of Vermont Medical Center